机构：[1]Brigham & Women’s Hospital, Harvard Medical School, Boston, MA[2]Institute of Cardiology and Center of Excellence on Aging, G. d’Annunzio University, Chieti, Italy[3]Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York[4]TIMI Study Group (Thrombolysis in Myocardial Infarction), Boston, MA[5]Daiichi Sankyo Pharma Development, Edison, NJ
第一作者机构：[1]Brigham & Women’s Hospital, Harvard Medical School, Boston, MA
通讯作者：
通讯机构：[4]TIMI Study Group (Thrombolysis in Myocardial Infarction), Boston, MA[*1]TIMI Study Group, 350 Longwood Ave, 1st Floor, Boston, MA 02115
推荐引用方式(GB/T 7714)：
Anthony P. Carnicelli,Raffaele De Caterina,Jonathan L. Halperin,et al.Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves[J].CIRCULATION.2017,135(13):1273-1275.doi:10.1161/CIRCULATIONAHA.116.026714.
APA：
Anthony P. Carnicelli,Raffaele De Caterina,Jonathan L. Halperin,Giulia Renda,Christian T. Ruff...&On behalf of the ENGAGE AF-TIMI 48 Investigators.(2017).Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves.CIRCULATION,135,(13)
MLA：
Anthony P. Carnicelli,et al."Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves".CIRCULATION 135..13(2017):1273-1275
医学